ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 92 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 6.67 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,350,035 | -23.6% | 719,014 | -2.0% | 0.00% | – |
| Q2 2023 | $5,692,829 | +807.3% | 733,612 | +566.4% | 0.00% | – |
| Q1 2023 | $627,456 | -51.6% | 110,080 | -50.0% | 0.00% | – |
| Q4 2022 | $1,296,742 | +268.4% | 220,160 | +100.0% | 0.00% | – |
| Q3 2022 | $352,000 | -28.6% | 110,080 | 0.0% | 0.00% | – |
| Q2 2022 | $493,000 | -84.4% | 110,080 | -81.5% | 0.00% | – |
| Q1 2022 | $3,170,000 | -83.0% | 593,549 | -53.3% | 0.00% | -100.0% |
| Q4 2021 | $18,696,000 | -15.6% | 1,271,828 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $22,162,000 | +0.1% | 1,059,899 | -15.3% | 0.00% | 0.0% |
| Q2 2021 | $22,146,000 | -33.8% | 1,251,913 | -8.3% | 0.00% | -50.0% |
| Q1 2021 | $33,456,000 | +175.3% | 1,365,565 | +280.3% | 0.00% | +100.0% |
| Q4 2020 | $12,154,000 | +303.9% | 359,043 | +198.4% | 0.00% | – |
| Q3 2020 | $3,009,000 | -9.0% | 120,320 | +22.8% | 0.00% | – |
| Q2 2020 | $3,305,000 | – | 97,991 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |